Skip to search formSkip to main contentSkip to account menu

denileukin diftitox/dexamethasone

Known as: DAB389-IL2/DM 
National Institutes of Health

Related topics

Related topics

2 relations
Dexamethasonedenileukin diftitox

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Introduction:Denileukin diftitox, a chimeric protein, uses the cytocidal properties of diphtheria toxin to cells expressing… 
2008
2008
Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
Highly Cited
2007
Highly Cited
2007
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
CD4+CD25+Foxp3+ regulatory T (Treg) cells have been implicated in the lack of effective antitumor immunity. Denileukin diftitox… 
2007
2007
Vision loss following denileukin diftitox treatment: A case report of possible posterior ischemic optic neuropathy
Denileukin diftitox (DD; Ontak, Eisai, Woodcliff Lake, NJ) is an FDA-approved targeted therapy for cutaneous T-cell lymphoma… 
2006
2006
Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
BACKGROUND Denileukin diftitox, a fusion protein consisting of peptide sequences for the enzymatically active and membrane… 
Highly Cited
2005
Highly Cited
2005
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma
Elimination of regulatory T lymphocytes may provide a way to break self-tolerance and unleash the anti-tumor properties of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)